Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

176.99 +0.05 (+0.03%)
Official Closing Price Updated: 7:00 PM EDT, Jun 29, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,114,551
Open 177.22
Bid (Size) 176.43 (1)
Ask (Size) 177.69 (5)
Prev. Close 176.94
Today's Range 176.43 - 178.30
52wk Range 155.72 - 186.69
Shares Outstanding 2,628,679,824
Dividend Yield 2.28%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
NextEvo Naturals Releases Deep Penetrating CBD Body Recovery Cream
NextEvo Naturals, a premium supplement brand focused on revolutionizing the delivery of nutritional compounds, launched its CBD Body Recovery Cream. 
Via Benzinga
Novavax Stock Is in Prime Position For Speculation
NVAX stock is on the cusp of the FDA approval that has long eluded the firm, meaning now is the best time to speculate on Novavax. 
Via InvestorPlace

Performance

YTD
+3.18%
+3.18%
1 Month
-1.41%
-1.41%
3 Month
-0.42%
-0.42%
6 Month
+3.90%
+3.90%
1 Year
+7.91%
+7.91%

More News

Read More
Portfolio Highlights: Quarterly Movers & Shakers, June 2022
Via Talk Markets
MeiraGTx Posts Encouraging Gene Therapy Data From Eye Disorder Trial
Via Benzinga
What Are Whales Doing With Johnson & Johnson
Via Benzinga
Why Did HC Wainwright Downgrade Addex Therapeutics
Via Benzinga
Legend Biotech Shares Move Higher After Bullish BMO Pitch
Via Benzinga
Addex Stops Parkinson's-Associated Dyskinesia Trial - Read Here Why
Via Benzinga
SciSparc And Polyrizon Report Joining Forces To Develop A Non-Opioid Pain Relief Nasal Spray
Via Benzinga
True Or False: Can These 5 High-Quality Stocks Really Be Recession Proof?
Via Talk Markets
From Axcella To Tonix, Here Are The Penny Stocks Of Companies Working On Long Covid
Via Investor's Business Daily
Tigecycline Market Development Factors 2022-2029 Pfizer, Hisun Pharma, Hansoh Pharma, HICIN Pharma, Amgen
Via SBWire
Topics Supply Chain
Exposures Supply Chain
This Biotech Company Says That It's Looking To Deliver A Breakthrough In Psychiatric Medicine — What's The Scoop?
Via Benzinga
Could This Company's Gastrointestinal Drug Be A Powerful Pill For People And Animals With Chronic, Debilitating Diarrhea?
Via Benzinga
With Zero Revenue, Laekna Plays Chicken-And-Egg Game With Investors
Via Benzinga
7 Large-Cap Stocks to Buy After the Next Big Correction
Via InvestorPlace
Global Medical Box Market 2022: Latest Global Research Report and Analysis by Regions 2029 : 3M, Johnson & Johnson, Acme United, ZEE, Certified Safety
Via SBWire
Topics Supply Chain
Exposures Supply Chain
Here's How Much You Would Have Made Owning Johnson & Johnson Stock In The Last 15 Years
Via Benzinga
7 Retirement Stocks to Buy After Age 30
Via InvestorPlace
Global Radioligand Therapy Market | Key Players are Johnson & Johnson Services, Inc., Pfizer Inc., Bayer AG, Molecular Partners, ITM Isotope Technologies Munich SE, Amneal Pharmaceuticals LLC, Novartis International AG and many more.
Via iCrowdNewswire
Check Out What Whales Are Doing With JNJ
Via Benzinga
Bear Market 2022: Is There Anything Left to Invest In?
Via InvestorPlace
Economic Hurricane Ahead? 7 Profitable Places to Hide Your Money
Via InvestorPlace
7 Stocks to Buy If You Have $1,000 to Invest
Via InvestorPlace
Looking At Johnson & Johnson's Recent Whale Trades
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.